CP
SGMT icon

Caligan Partners’s Sagimet Biosciences SGMT Stock Holding History

Caligan Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Buy
+2,500,000
New +$17M 0.91% 21

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Caligan Partners's SGMT Position: Q2 2026 in Review

Caligan Partners opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 2,500,000 shares worth $19.3M. The stake represents 0.91% of the portfolio and ranks #21 among its holdings.

110 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Caligan Partners held 2,500,000 shares of Sagimet Biosciences worth $19.3M as of Q2 2026.
  • Sagimet Biosciences was a new Caligan Partners position in Q2 2026.
  • Sagimet Biosciences made up 0.91% of Caligan Partners's portfolio in Q2 2026, its #21 holding.
  • 110 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.